Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinson’s disease

In pursuit of treating Parkinson’s disease with cell replacement therapy, differentiated induced pluripotent stem cells (iPSC) are an ideal source of midbrain dopaminergic (mDA) cells. We previously established a protocol for differentiating iPSC-derived post-mitotic mDA neurons capable of reversing...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiller, Benjamin M., Marmion, David J., Thompson, Cayla A., Elliott, Nathaniel A., Federoff, Howard, Brundin, Patrik, Mattis, Virginia B., McMahon, Christopher W., Kordower, Jeffrey H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023503/
https://www.ncbi.nlm.nih.gov/pubmed/35449132
http://dx.doi.org/10.1038/s41536-022-00221-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023503/
https://www.ncbi.nlm.nih.gov/pubmed/35449132
http://dx.doi.org/10.1038/s41536-022-00221-y

Ejemplares similares